Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for CNBX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
May 31, 2026 0.00
February 28, 2026 0.00
November 30, 2025 0.00
August 31, 2025 0.00
May 31, 2025 0.00
February 28, 2025 0.00
November 30, 2024 0.00
August 31, 2024 0.00
May 31, 2024 0.0947M
February 29, 2024 0.02M
November 30, 2023 -0.0012M
August 31, 2023 0.00
May 31, 2023 0.00
February 28, 2023 0.0247M
November 30, 2022 0.00
August 31, 2022 0.0257M
May 31, 2022 0.00
February 28, 2022 0.00
November 30, 2021 -0.0005M
August 31, 2021 0.00
May 31, 2021 0.00
February 28, 2021 0.646M
November 30, 2020 -0.0009M
August 31, 2020 1.134M
May 31, 2020 0.3463M
Date Value
February 29, 2020 0.9913M
November 30, 2019 0.815M
August 31, 2019 0.6412M
May 31, 2019 -3.856M
February 28, 2019 -0.7402M
November 30, 2018 -1.296M
August 31, 2018 -0.7003M
May 31, 2018 -0.0983M
February 28, 2018 -0.6394M
November 30, 2017 -0.0045M
August 31, 2017 -0.0347M
May 31, 2017 -0.0893M
February 28, 2017 -0.0017M
November 30, 2016 0.00
August 31, 2016 0.00
May 31, 2016 0.00
February 29, 2016 0.00
November 30, 2015 0.00
August 31, 2015 0.0007M
May 31, 2015 0.00
February 28, 2015 0.00
November 30, 2014 -0.0037M
August 31, 2014
May 31, 2014 -0.03M
February 28, 2014 0.00

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 0.00
GB Sciences, Inc. --
Arvinas, Inc. 54.90M
Fulcrum Therapeutics, Inc. 13.78M
Definium Therapeutics, Inc. -315.46M